Infusion of bcr/abl peptide-reactive donor T cells to achieve molecular remission of chronic myeloid leukemia after CD34+ selected allogeneic hematopoietic cell transplantation [9]

Leukemia

Volumn 20, Issue 11, 2006, Pages 2055-2057

  Bornhauser, Martin ^a   Thiede, C ^a   Babatz, J ^a   Schetelig, J ^a   Illmer, T ^a   Kiani, A ^a   Platzbecker, U ^a   Herr, W ^b   Rieber, E P ^a   Ehninger, G ^a   Schmitz, M ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CYCLOSPORIN A; FLUDARABINE; GLYCYLPHENYLALANYLLYSYLGLUTAMINYLSERYLSERYLLYSYLALANYLLEUCINE; GRANULOCYTE COLONY STIMULATING FACTOR; HLA ANTIGEN CLASS 1; IMATINIB; PEPTIDE DERIVATIVE; PROPYLPROPYLLYSYLALANYLLEUCYLGLUTAMINYLARGINYLPROLYLVALINE; THIOTEPA; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; VALYLLEUCYLGLUTAMINYLGLUTAMYLLEUCYLASPARAGINYLVALYLTHREONYLVALINE;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CASE REPORT; CD34 SELECTION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; WHOLE BODY RADIATION;

EID: 33750310835     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404383     Document Type: Letter

References (11)

1. Goldman JM, Melo JV. Chronic myeloid leukemia - advances in biology and new approaches to treatment. N Engl J Med 2003; 349: 1451-1464.
2. Marmont AM, Horowitz MM, Gale RP, Sobocinski K, Ash RC, van Bekkum DW et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991; 78: 2120-2130.
3. Luznik L, Fuchs EJ. Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation. Cancer Control 2002; 9: 123-137.
4. Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000; 6: 1018-1023.
5. Yotnda P, Firat H, Garcia-Pons F, Garcia Z, Gourru G, Vernant JP et al. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest 1998; 101: 2290-2296.
6. Norbury LC, Clark RE, Christmas SE. b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia. Br J Haematol 2000; 109: 616-621.
7. Butt NM, Rojas JM, Wang L, Christmas SE, Abu-Eisha HM, Clark RE. Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients and healthy subjects. Haematologica 2005; 90: 1315-1323.
8. Babatz J, Rollig C, Lobel B, Folbrecht G, Haack M, Gunther H et al. Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. Cancer Immunol Immun 2006; 55: 268-276.
9. Kiessling A, Schmitz M, Stevanovic S, Weigle B, Holig K, Fussel M et al. Prostate stem cell antigen: Identification of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patients. Int J Cancer 2002; 102: 390-397.
10. Falkenburg JH, Wafelman AR, Joosten P, Smit WM, van Bergen CA, Bongaerts R et al. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood 1999; 94: 1201-1208.
11. Elmaagacli AH, Peceny R, Steckel N, Trenschel R, Ottinger H, Grosse-Wilde H et al. Outcome of transplantation of highly purified peripheral blood CD34+ cells with T-cell add-back compared with unmanipulated bone marrow or peripheral blood stem cells from HLA-identical sibling donors in patients with first chronic phase chronic myeloid leukemia. Blood 2003; 101: 446-453.